moksha8,Inc. has expanded its strategic partnership with Rocheto commercialize an additional portfolio of products in Mexico currentlygenerating sales of $140 million USD. moksha8 will commercialize products in three therapeutic areas, CNSdisease, anti-infectives, and inflammation. The product portfolio consists ofwell-known brands including Rivotril(R), Rocephin(R) and Bactrim(R).”moksha8 has produced strong results for Roche in Brazil and we aredelighted to expand our relationship to include Mexico as a key country inLatin America,” said Ernest Egli, President of Roche Latin America. “moksha8brings strong commercial capabilities and innovative marketing to our CNS,anti-infectives and inflammation franchises. We look forward to continuingthis valuable relationship.” “moksha8 has established a broad footprint in Latin America with leadingproducts that are cornerstones of medical care,” said Simba Gill, CEO ofmoksha8. “We look forward to continuing our strong relationship with Rocheand driving value from this important portfolio of products. We are nowfirmly positioned as the leading partner of choice for pharmaceutical andbiotechnology companies looking to generate value across Latin America.”In just over a year, moksha8 has grown its commercial organization to over200 employees in Brazil and Mexico and a portfolio of products with sales of$200 million USD. moksha8 is uniquely positioned as the leading specialtypharmaceutical company in Latin America with a strong presence in CNS,anti-infectives and inflammation.